TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients with symptomatic PAH (Idiopathic, Familial, Associated PAH due to connective tissue disease, congenital heart disease, portal hypertension with liver cirrhosis, or due to anorexigen or amphetamine use)~* Treatment naive patients and patients pre-treated with an Endothelin Antagonist or a Prostacyclinanalogue (except I.V.).~Exclusion Criteria:~* All types of pulmonary hypertension except subtypes of Venice Group I specified in the inclusion criteria, severe COPD (chronic obstructive pulmonary disease), uncontrolled arterial hypertension, left heart failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Riociguat (Adempas, BAY63-2521) up to 2.5 mg_IDT (Type: EXPERIMENTAL): Participants received Riociguat orally as a film-coated tablet up to 2.5mg three times daily (tid) (titration between 1.0 mg and 2.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks
- Riociguat (Adempas, BAY63-2521) up to 1.5 mg_IDT (Type: EXPERIMENTAL): Participants received Riociguat orally as a film-coated tablet up to 1.5mg three times daily (tid) (titration between 1.0 mg and 1.5 mg tid based on an individual dose titration (IDT) scheme) for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Participants received Placebo orally as a film-coated tablet three times daily (tid) for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Diagnosed with type 2 diabetes~* On a stable dose of metformin of at least 1500 mg per day~Exclusion Criteria:~* History of type 1 diabetes~* Pregnant~* HIV positive~* On a weight loss program or medication~* Has a history of blood disorder, certain cancers, heart, liver or kidney disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): sitagliptin
- 2 (Type: ACTIVE_COMPARATOR): glimepiride

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days' Gestation in Kazakhstan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Have an intrauterine pregnancy consistent with gestational age less than 71 days;~* Be able to understand and willing to sign a consent form;~* Be eligible for medical abortion according to the clinician's assessment;~* Be able to return to the clinic and able to contact study staff or emergency medical services, if needed;~* Be willing to provide an address and/or telephone number for purposes of follow-up;~* Agree to comply with the study procedures and visit schedule.~Exclusion Criteria:~* Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass;~* Chronic renal failure;~* Concurrent long-term corticosteroid therapy;~* History of allergy to mifepristone, or misoprostol or another prostaglandin;~* History of hemorrhagic disorders or concurrent anticoagulant therapy;~* History of inherited porphyrias;~* Intrauterine device in place (must be removed before mifepristone is administered).

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Women seeking medical abortion (Type: None): Women with pregnancies less than 71 days gestation seeking medical abortion. Women who choose to participate in the study will be administered 200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Levobupivacaine to the Surgical Wound Following Cesarean

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Full-term pregnant women who undergo scheduled cesarean surgery under intradural anesthesia.~* Duly informed patients who have signed the informed consent during the preanesthesia consultation, or after a period of consideration if necessary, expressing their consent to be included in the study.~* Between 18-45 years of age.~* ASA I and II.~* Sufficient intellectual ability to understand the technique as well as the equipment being used.~Exclusion Criteria:~* Failure to meet any of the above criteria.~* Presence of a major medical, cardiovascular, pulmonary, metabolic, renal or liver disorder.~* Preeclampsia and/or HELLP syndrome.~* Coagulopathy~* Profuse bleeding greater than 1000 ml or that which provokes hemodynamic instability that requires aggressive fluid therapy and/or transfusion.~* Allergy to any drug included in the protocol.~* Psychiatric or neurological pathology.~* Preexisting infection.~* Previous treatment with opioids or antidepressants or suffer from chronic pain.~* History of alcohol or drug abuse or known consumption of medications that interfere with LB metabolism.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Levobupivacaine (Type: EXPERIMENTAL): Continuous levobupivacaine subfascial infusion
- NaCl (Type: PLACEBO_COMPARATOR): Continuous NaCl subfascial infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals who aged 18 to 65 years~* Meet the diagnosis of schizophrenia according to DSM-IV~* Monotherapy of atypical antipsychotics for 4 weeks or more~* At least 60 for Positive and Negative Syndrome Scale (PANSS)~* Female subjects will be eligible to participate in the study if they are of non-childbearing potential or of child-bearing potential~* Sign the informed consent form~Exclusion Criteria:~* Individuals who with diagnosis of other psychiatric disorders except schizophrenia according to DSM-IV~* Refused to provide informed consent~* Significant medical illnesses including uncontrolled hypertension, diabetes, seizure disorder, severe cardiovascular, cerebrovascular, pulmonary, or thyroid diseases~* Currently on anti-inflammatory or immunosuppressant medication including oral steroids and history of chronic infection (including tuberculosis, HIV and hepatitis), malignancy, organ transplantation, blood dyscrasia, central nervous system demyelinating disorder, and any other known autoimmune or inflammatory condition.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 62 Years
- Healthy Volunteers: f

Study Arms:
- berberine group (Type: EXPERIMENTAL): None
- control group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Male or female at least 18 years of age at time of screening who is determined to be eligible based on evaluation by a treating provider,~ 2. Documentation of genotype 1 (GT-1) infection, liver fibrosis staging by any AASLD/IDSA guideline approved measurement, and HIV status determination.~ 3. Chronic HCV genotype-1 infection prior to study enrollment. Chronic HCV-infection is defined as the following: positive for anti-HCV Ab or HCV RNA at least 6 months before screening, and positive for HCV RNA and anti-HCV Ab at the time of screening~ 4. Compensated liver disease, both with and without cirrhosis, as determined clinically by referring provider~ 5. If coinfected with HIV, stable HIV disease as determined by a treating provider~ 6. Subjects must be able to understand and adhere to the study visit schedule and all other protocol requirements, and must voluntarily sign and date an informed consent form, approved by an Institutional Review Board (IRB), prior to the initiation of any screening or study specific procedures.~EXCLUSION CRITERIA:~1. Women who are pregnant or breastfeeding~2. Screening laboratory analyses showing any of the following abnormal laboratory results:~   - Estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min as estimated by the Modification of Diet in Renal Disease (MDRD) equation (utilized by LabCorp):~   eGFR = 175 times SerumCr(-1.154) age(-0.203 1.212 (if patient is black) 0.742 (if female)~3. Diagnosis of hepatocellular carcinoma as defined by pre-screening medical history~4. Any other conditions in the opinion of the investigator that would interfere with the compliance or endpoints of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: OTHER): Standard of care treatment using Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination by mouth daily for 2, 3, or 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Women with Stage I - II breast cancer~* Ages 40 - 55~* Pre- or peri-menopausal~* Within 1 month of beginning adjuvant or neoadjuvant chemotherapy~* Baseline lumbar spine and total hip BMD \> -2.0 SD~* Able to read and write English~* Signed consent form~Exclusion Criteria:~* Previous treatment with bisphosphonates~* Laboratory evidence of renal disease~* Previous TRAM flap reconstructive surgery~* Positive pregnancy test~* Mental illness that precludes the patient from giving informed consent~* Laboratory evidence of hepatic disease

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female neonate or infant up to 1 year of age with Fitzpatrick Skin Type I-VI~* Clinical evidence of diaper dermatitis and a positive KOH result for pseudohyphae and/or budding yeast at baseline visit~* Overall Diaper Dermatitis Severity Index score at baseline visit of 4-8 (must include an overall clinical grade of at least 2 for erythema)~* Wear commercially available diapers day and night for at least 7 days prior to enrollment and during the course of the 2 year study~* Caretaker must complete informed consent process~Exclusion Criteria:~* Known sensitivity to any component of the formulation~* No other skin conditions that may confound the evaluation of the drug efficacy or tolerability~* Known sensitivity to skin care toiletry products or diapers~* History of HIV positive~* Chronic illnesses that require systemic medication that may confound the evaluation of study drug efficacy or tolerability (antibiotic therapy is not included)~* Treatment with a prescription product for diaper dermatitis or other skin condition 7 days prior to enrollment

- Gender: ALL
- Minimum Age: None
- Maximum Age: 15 Months
- Healthy Volunteers: f

Study Arms:
- Miconazole Nitrate (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Organizational Skills Training - Tier 2 (OST-T2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Any student enrolled in grades 3 through 5 in one of the participating schools who meets the following criteria.~1. First, students will be recommended by their general education teacher if the following are true: (a) students who are struggling the most with OTMP skills, (b) whose OTMP skill deficits are the students' primary concern (c) whose academic performance is negatively impacted by their OTMP deficits, and (d) who have at least one parent who speaks English.~2. Second, students must have or be at risk for developing OTMP deficits.~Exclusion Criteria:~1. Students will be excluded if they are in a pull-out special education classroom for more than 50% of the day as the organizational demands for these students may differ from those students placed mostly in general education.~2. Students with a one-to-one aide will be excluded because the presence of an aide substantially alters how an organizational intervention is implemented.~3. Students from families in which both caregivers do not speak English will be excluded because the program has not yet been developed for non-English speakers.~4. Only one student per family will be included in the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OST-T2 Intervention group (Type: EXPERIMENTAL): Small group skills training for students in grades 3 through 5 with difficulties with organization, time management, and planning skills. Includes parent and teacher involvement to support student skills use.
- Treatment as usual control group (Type: NO_INTERVENTION): Strategies currently in use by schools to address organization, time management, and planning skills problems.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Outcome of Two Protocols in Poor Responders in Assisted Reproductive Technology (ART) Cycle

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Poor responders (Presence of at least two of following items is necessary for inclusion to the study)~* History of Cycle Cancellation~* History of oocyte number 3 (in previous cycle)~* History of Number of antral follicle \< 5 in previous cycle~* Age≥38~* FSH\>12 on day 2 or 3~* Ovarian Volume 3 cm3~Exclusion Criteria:~* Male factor (azospermi)~* Myoma ≥6cm~* One way ovary~* Tumor or cyst \>13mm~* Age \>42

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 42 Years
- Healthy Volunteers: f

Study Arms:
- Flare Up (Type: ACTIVE_COMPARATOR): Flare up protocol in poor responders for IVF/ICSI
- Microdose GnRh (Type: EXPERIMENTAL): Microflare protocol in poor responders for IVF/ICSI

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Testosterone Replacement in Men With Diabetes and Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* T2D arm: Males with age 30-65 years~* Obese non-diabetic arm: Obese non-diabetic males with age 30-65 years~Exclusion Criteria:~1)Coronary event or procedure(myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous twelve weeks; 2) PSA \> 4ng/ml; 3)Hemoglobin A1c \> 8%; 4)h/o prostate carcinoma; 5)Hepatic disease (transaminase \> 3 times normal) or cirrhosis; 6)Renal impairment (defined as GFR\<30); 7)HIV or Hepatitis C positive status; 9)Participation in any other concurrent clinical trial; 10)Any other life-threatening, non-cardiac disease; 11)Use of over the counter health supplements which contain androgens; 12)Use of an investigational agent or therapeutic regimen within 30 days of study; 13)prostate nodule or severe enlargement on digital rectal examination; 14)Use of testosterone currently or in the past 4 months; 15)Hematocrit \> 50%; 16)History of untreated severe obstructive sleep apnea(defined as apnea-hypopnea index ≥30); 17)symptoms suggestive of severe BPH; 18)Congestive heart failure, class III or IV; 20)Known to have anemia secondary to iron, B12 or folic acid deficiency; 21)bone marrow disorder such as myelodysplasia or aplastic anemia; 22) currently suffering from symptomatic depression, with or without treatment; 23) history of severe depression in the past which needed hospitalization; 24)currently suffering from foot ulcer, significant periodontal disease or any other chronic infectious condition; 25)planning to have children. 26) Subjects on testosterone or with testosterone replacement in the past 4 months will be excluded.

- Gender: MALE
- Minimum Age: 30 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- diabetes with HH-active (Type: ACTIVE_COMPARATOR): Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
- diabetes with normal testosterone (Type: NO_INTERVENTION): Eugonadal subjects with diabetes. They will not be treated
- obese with HH-active (Type: ACTIVE_COMPARATOR): Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to testosterone intervention.
- obese with normal testosterone (Type: NO_INTERVENTION): Eugonadal non-diabetic obese subjects. They will not be treated
- Diabetes with HH-placebo (Type: PLACEBO_COMPARATOR): Subjects with diabetes and hypogonadotropic hypogonadism. They will be randomized to placebo.
- Obese with HH-placebo (Type: PLACEBO_COMPARATOR): Obese non-diabetic men hypogonadotropic hypogonadism. They will be randomized to placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Participant has a diagnosis of essential hypertension~* Participant is being treated with a single, or dual combination treatment for hypertension and will be able to discontinue the prior antihypertensive medication~* Participant has a mean trough SiDBP of ≥ 90 mmHg and \< 110 mmHg~* Participant has a mean trough SiSBP of ≥ 140 mmHg and \< 200 mmHg~* Participant has no clinically significant abnormality at screening visit~Exclusion criteria:~* Participant is currently taking \>2 antihypertensive medications~* Participant has a history of significant multiple and/or severe allergies to ingredients of Nu-Lotan or Preminent, amlodipine or dihydropyridine drug and thiazide drug or related drug (i.e., sulfonamide-containing chlortalidone medicines)~* Participant is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history within the last year of drug or alcohol abuse or dependence~* Participant is pregnant or breastfeeding, or expecting to conceive OR the pregnancy test is positive at screening visit (Visit 1)~* Participant is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- L50/H12.5/A5→L50/H12.5/A5 (Type: EXPERIMENTAL): One combination tablet containing L50 mg, H12.5 mg, and A5 mg, orally, once daily, for up to 8 weeks (double-blind treatment period). Participants continue with once daily L50/H12.5/A5 for 44 weeks during open label extension.
- L50/H12.5→L50/H12.5/A5 (Type: ACTIVE_COMPARATOR): One combination tablet containing L50 mg and H12.5 mg, orally, once daily, for up to 8 weeks during double-blind treatment period. Participants then receive once daily L50/H12.5/A5 for 44 weeks during open-label extension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete